|
|
|
|
| LEADER |
01862nam a2200337 u 4500 |
| 001 |
EB001999846 |
| 003 |
EBX01000000000000001162747 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Yu, Changhua
|
| 245 |
0 |
0 |
|a Intravitreal dexamethasone implants for non-infectious uveitis
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Changhua Yu, Danielle MacDougall
|
| 246 |
3 |
1 |
|a Ozurdex for uveitis
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, March 25, 2020
|
| 300 |
|
|
|a 1 PDF file (24 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Intravitreal Injections / methods
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Practice Guidelines as Topic
|
| 653 |
|
|
|a Uveitis / drug therapy
|
| 700 |
1 |
|
|a MacDougall, Danielle
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK562949
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to review the clinical effectiveness, safety, cost-effectiveness of IDI in the treatment of NIU. Of particular interest is evidence on different dose regimens of IDI (e.g., a single implant or two implants with approximately six months between doses, or continual treatment (i.e., three or more implants) or implants at intervals of less than every six months). In addition, this report also reviews the evidence-based guidelines on the treatment of NIU.
|